Pramlintide

Also known as: Symlin, AC137

**Mechanism of Action** Pramlintide (Symlin, AC137) is a synthetic analog of human amylin, a neuroendocrine hormone co-secreted with insulin by pancreatic β-cells. As an adjunct to mealtime insulin, it exerts three primary glucoregulatory effects: (1) slowing gastric emptying via vagal-mediated pathways, which delays postprandial glucose absorption; (2) suppressing glucagon secretion from pancreatic α-cells, reducing hepatic glucose output; and (3) enhancing central satiety signaling through amylin receptors in the area postrema, leading to reduced caloric intake. These actions collectively attenuate postprandial hyperglycemia and improve glycemic variability. **Key Research Findings** Clinical trials demonstrate that pramlintide, when added to intensive insulin therapy in type 1 and type 2 diabetes, reduces HbA1c by 0.3–0.6% and decreases postprandial glucose excursions by 30–50%. It also promotes modest weight loss (1–3 kg over 6 months), contrasting with insulin-associated weight gain. Nausea is the most common adverse effect, typically transient and dose-dependent. Long-term studies confirm sustained efficacy without tachyphylaxis, though hypoglycemia risk increases if insulin doses are not appropriately reduced. **Clinical Relevance** Pramlintide is FDA-approved for type 1 and type 2 diabetes as an adjunct to mealtime insulin in patients with inadequate glycemic control despite optimized insulin therapy. Its unique amylin-mimetic profile addresses residual postprandial hyperglycemia and weight gain, offering a complementary mechanism to insulin. However, its utility is limited by the need for separate premeal injections, gastrointestinal side effects, and strict insulin dose adjustments to mitigate hypoglycemia. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides